Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) CEO Vlad Coric sold 51,962 shares of Biohaven Pharmaceutical stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $50.15, for a total transaction of $2,605,894.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Vlad Coric also recently made the following trade(s):

  • On Thursday, March 14th, Vlad Coric sold 100,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $50.09, for a total transaction of $5,009,000.00.

Biohaven Pharmaceutical stock opened at $50.10 on Friday. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -8.16 and a beta of 0.46. Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $16.50 and a twelve month high of $50.65.

Several analysts have weighed in on BHVN shares. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Biohaven Pharmaceutical in a research note on Friday, February 8th. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Tuesday, January 15th. ValuEngine raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Piper Jaffray Companies set a $65.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 10th. Finally, Oppenheimer set a $63.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 3rd. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $53.00.

Several large investors have recently modified their holdings of BHVN. Flinton Capital Management LLC bought a new position in shares of Biohaven Pharmaceutical during the fourth quarter valued at about $42,000. Neuburgh Advisers LLC bought a new position in shares of Biohaven Pharmaceutical during the fourth quarter valued at about $52,000. Tower Research Capital LLC TRC raised its stake in shares of Biohaven Pharmaceutical by 602.4% during the third quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock valued at $190,000 after acquiring an additional 4,337 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Biohaven Pharmaceutical by 14.1% during the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock valued at $196,000 after acquiring an additional 652 shares during the last quarter. Finally, Shell Asset Management Co. bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at about $205,000. 97.60% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Sells $2,605,894.30 in Stock” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2019/03/17/biohaven-pharmaceutical-holding-co-ltd-bhvn-ceo-sells-2605894-30-in-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Featured Article: What is the downside to momentum investing?

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.